Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RV 01 - Radiopharm Ventures

Next Previous
Drug Profile

RV 01 - Radiopharm Ventures

Alternative Names: 177Lu-BetaBart; 177lutetium BetaBart; 177Lutetium-conjugated B7-H3 radioantibody; Lu177-B7H3-mAb; Radiolabelled humanized IgG antibody - Radiopharm Venture; Radiolabelled humanized immunoglobulin G antibody - Radiopharm Ventures; RV-01 - Radiopharm Ventures

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radiopharm Ventures
  • Developer Radiopharm Ventures; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 24 Feb 2026 Pharmacodynamics data from a preclinical trial in Solid tumours released by Radiopharm Theranostics
  • 15 Jan 2026 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT07189871)
  • 12 Jan 2026 Radiopharm Ventures plans a first-in-human phase I trial for Solid tumours in USA (Parenteral), in first quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top